⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 2024

Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Sean R. Corcoran James D. Phelan Jaewoo Choi Galina Shevchenko Rachel E. Fenner Xin Yu Sebastian Scheich Tony Hsiao Vivian M. Morris Evangelia K. Papachristou Kamal Kishore Clive S. D’Santos Yanlong Ji Stefania Pittaluga George W. Wright Henning Urlaub Kuan‐Ting Pan Thomas Oellerich Jagan Muppidi Daniel J. Hodson Louis M. Staudt

View at Publisher

Ask AI

Bookmark

Share

Abstract

Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Corcoran et al. (2024) studied this question.

synapsesocial.com/papers/68e59691b6db643587531431 https://doi.org/10.1158/2159-8290.26935082

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024
2Supplementary Figure S8 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024
3Supplementary Figure S8 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024
4Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024
5Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024

More related papers

Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024
Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024
Supplementary Figure S15 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma2024